Harbor Capital Advisors Inc. Boosts Position in Castle Biosciences, Inc. (NASDAQ:CSTL)

Harbor Capital Advisors Inc. grew its stake in shares of Castle Biosciences, Inc. (NASDAQ:CSTL) by 11.0% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 153,907 shares of the company’s stock after buying an additional 15,200 shares during the period. Harbor Capital Advisors Inc.’s holdings in Castle Biosciences were worth $4,389,000 at the end of the most recent reporting period.

Other large investors also recently modified their holdings of the company. Vanguard Group Inc. lifted its stake in Castle Biosciences by 2.2% in the 1st quarter. Vanguard Group Inc. now owns 1,494,176 shares of the company’s stock worth $33,096,000 after purchasing an additional 32,695 shares in the last quarter. Acadian Asset Management LLC raised its position in shares of Castle Biosciences by 130.7% in the first quarter. Acadian Asset Management LLC now owns 210,824 shares of the company’s stock worth $4,669,000 after buying an additional 119,443 shares in the last quarter. Summit Global Investments bought a new stake in Castle Biosciences during the second quarter valued at $518,000. SG Americas Securities LLC purchased a new position in Castle Biosciences during the second quarter worth about $588,000. Finally, Inspire Investing LLC bought a new position in Castle Biosciences in the 2nd quarter worth about $809,000. 92.60% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on CSTL. BTIG Research lifted their price target on Castle Biosciences from $35.00 to $40.00 and gave the company a “buy” rating in a research report on Monday, October 14th. Canaccord Genuity Group lifted their target price on shares of Castle Biosciences from $35.00 to $42.00 and gave the company a “buy” rating in a research report on Tuesday, October 29th. Stephens reissued an “overweight” rating and issued a $37.00 price target on shares of Castle Biosciences in a report on Tuesday, August 6th. Finally, Robert W. Baird lifted their price objective on shares of Castle Biosciences from $34.00 to $37.00 and gave the stock an “outperform” rating in a report on Tuesday, August 6th. Seven investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock currently has an average rating of “Buy” and an average price target of $35.14.

Castle Biosciences Trading Down 4.4 %

Shares of CSTL opened at $33.15 on Monday. The company has a debt-to-equity ratio of 0.02, a quick ratio of 7.92 and a current ratio of 8.12. Castle Biosciences, Inc. has a fifty-two week low of $16.14 and a fifty-two week high of $35.42. The firm has a 50 day moving average price of $30.57 and a 200-day moving average price of $25.48. The firm has a market cap of $915.27 million, a price-to-earnings ratio of -236.79 and a beta of 0.98.

Castle Biosciences (NASDAQ:CSTL) last posted its quarterly earnings results on Monday, August 5th. The company reported $0.31 earnings per share for the quarter, topping the consensus estimate of ($0.16) by $0.47. Castle Biosciences had a negative net margin of 1.08% and a negative return on equity of 0.77%. The business had revenue of $87.00 million during the quarter, compared to the consensus estimate of $69.95 million. During the same period in the previous year, the firm posted ($0.70) earnings per share. As a group, equities research analysts forecast that Castle Biosciences, Inc. will post -0.58 earnings per share for the current year.

Insider Transactions at Castle Biosciences

In related news, insider Derek J. Maetzold sold 986 shares of the firm’s stock in a transaction that occurred on Friday, October 4th. The stock was sold at an average price of $28.73, for a total transaction of $28,327.78. Following the transaction, the insider now directly owns 94,622 shares in the company, valued at $2,718,490.06. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In other Castle Biosciences news, insider Derek J. Maetzold sold 986 shares of the stock in a transaction on Friday, October 4th. The shares were sold at an average price of $28.73, for a total transaction of $28,327.78. Following the completion of the sale, the insider now owns 94,622 shares of the company’s stock, valued at $2,718,490.06. This represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, CFO Frank Stokes sold 10,000 shares of the firm’s stock in a transaction on Wednesday, August 7th. The stock was sold at an average price of $25.70, for a total transaction of $257,000.00. Following the completion of the sale, the chief financial officer now directly owns 30,823 shares in the company, valued at approximately $792,151.10. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 29,694 shares of company stock worth $820,497. Company insiders own 7.20% of the company’s stock.

Castle Biosciences Profile

Castle Biosciences, Inc, a molecular diagnostics company, provides testing solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus, uveal melanoma, and mental health conditions. It offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma; DecisionDx-SCC, a proprietary risk stratification GEP test for patients with cutaneous squamous cell carcinoma; MyPath Melanoma, a test used for patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a spatial omics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, or low-grade dysplasia Barrett's esophagus.